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Abstract
Background: Phosphoprotein phosphatase 2A (PP2A), a major serine-threonine protein phosphatase in eukaryotes, is an
oligomeric protein comprised of structural (A) and catalytic (C) subunits to which a variable regulatory subunit (B) can
associate. The C subunit contains a methyl ester post-translational modification on its C-terminal leucine residue, which is
removed by a specific methylesterase (PME-1). Methylesterification is thought to control the binding of different B subunits
to AC dimers, but little is known about its physiological significance in vivo.
Methodology/PrincipalFindings:Here, we show that targeteddisruptionof the PME-1 gene causesperinatal lethalityinmice,
a phenotype that correlates with a virtually complete loss of the demethylated form of PP2A in the nervous system and
peripheral tissues. Interestingly, PP2A catalytic activity over a peptide substrate was dramatically reduced in PME-1(2/2)
tissues, which also displayed alterations in phosphoproteome content.
Conclusions: These findings suggest a role for the demethylated form of PP2A in maintenance of enzyme function and
phosphorylation networks in vivo.
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Introduction
Reversible protein phosphorylation regulated by the coordinat-
ed action of protein kinases and phosphatases is an essential
signaling mechanism for most cellular processes. Post-translational
phosphorylation is predicted to occur on more than 30% of all
eukaryotic proteins [1]. While phosphorylation is catalysed by
more than 500 characterized kinases, a relatively small number of
phosphatases are responsible for removing protein phosphoryla-
tion sites [2]. In mammalian cells, phosphoprotein phosphatase 2A
(PP2A), together with PP1, account for .90% of the total serine/
threonine phosphatase activity [3]. PP2A is a ubiquitously
expressed multimeric protein that is highly conserved across
eukaryotes ranging from yeast to human. PP2A is involved in
numerous cellular processes, including signal transduction path-
ways that regulate mitogenic and survival signals, transcriptional
and translational events, and the cell cycle [4,5]. Moreover, several
studies have identified alterations in specific PP2A subunits in
human cancers, which has led to the hypothesis that PP2A serves
as a tumor suppressor [6,7].
Despite the central role that PP2A plays in cell signaling, the
biochemical mechanisms that regulate PP2A activity in vivo are
poorly understood. This is in part due to the complex composition
and post-translational modification of PP2A. Structurally, it is a
heterotrimeric complex typically consisting of a catalytic subunit
(C), a scaffolding subunit (A or PR65) and one of an array of
different regulatory subunits. In mammalian cells, the A and C
subunits each have two isoforms (a and b), which share high
sequence similarity. However, the most variable component of the
holoenzyme is the regulatory subunit, which can belong to one of
four different families termed B (or PR55), B9 (or B56 or PR61), B0
(or PR72) and B’’’ (or PR93/PR110). Each one of these gene
families encodes multiple isoforms and splice variants. The
different families of B subunits bind to overlapping regions on
the AC dimer so their association to the core enzyme is mutually
exclusive. Combinatorially, this variety of B subunits could
generate as many as 70 different holoenzyme assemblies [4].
The current model for regulation of PP2A suggests that
heterotrimers containing different regulatory subunits have distinct
functions in vivo [8]. More specifically, B subunits, which exhibit
cell- and tissue-restricted expression, are considered to be a major
determining factor of substrate specificity by, for example,
targeting PP2A to different intracellular locations [4,9]. For
example, the B subfamily has been shown to target PP2A to
microtubules [10] while the B56 subfamily interacts with cyclin G
and mediates PP2A functions in the Wnt/b-catenin and Erk
signalling cascades [11–13]. Further support for this model stems
from recent three-dimensional structural information obtained for
the AC core enzyme [14] and the trimeric holoenzyme [15,16].
The intrinsic flexibility of the A scaffolding subunit [14] as well as
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rearrangements after binding of the regulatory subunit [15,16],
has been proposed to be important for binding different regulatory
subunits and for performing catalysis on a wide variety of
substrates.
A further level of PP2A regulation is provided by post-
translational modification of the catalytic subunit, which can be
phosphorylated on Tyr
307, as well as on a threonine residue
[17,18]. In addition, a unusual type of reversible methylation
occurs at the carboxyl group of the C terminal Leu residue
(Leu
309) [19]. Carboxylmethylation of Leu
309 (referred to hereafter
as ‘‘methylation’’) is catalysed by a specific S-adenosylmethionine
dependent methyltransferase, termed leucine carboxylmethyl-
transferase (LCMT) [20,21]. The demethylation reaction is
catalysed by a specific PP2A methylesterase (PME-1), which has
been purified and molecularly characterized [22,23]. Whereas
phosphorylation of the catalytic subunit of PP2A inhibits enzyme
activity [17,18], a link between methylation of Leu
309 and PP2A
activity has remained contentious with different groups observing
opposed effects [4,19,20,24]. The current generally accepted view
is that methylation does not affect phosphatase activity in vitro,
suggesting instead that this modification indirectly regulates PP2A
activity by modulating the binding of different regulatory B
subunits to AC dimers [14,25–30]. By affecting the association of
the C subunit with regulatory subunits in vivo, methylation is
predicted to alter the targeting of PP2A to certain substrates and,
as a consequence, potentially impact a wide range of signalling
pathways [26]. Consistent with this model, disruption of the major
methyltransferase responsible for methylating PP2A in yeast leads
to severe growth defects [26]. On the other hand, deletion of the
yeast PME-1 gene did not result in an observable cellular
phenotype, even though PP2A methylation levels were enhanced
[26]. More recent studies have proposed new models about the
role of PME-1 in the regulation of PP2A. In the yeast, PME-1
seems to control the generation of active C subunit biogenesis and
holoenzyme assembly [31]. In mammalian cells, and consistently
with its predominant nuclear location, the major in vivo function
of PME-1 has been proposed to be the stabilization of the inactive
nuclear PP2A pool [32].
To more clearly understand the impact of methylation on PP2A
function in mammalian biology, we have created mice that lack
PME-1 by targeted gene disruption (PME-1(–/–) mice). Deletion
of PME-1 resulted in post-natal lethality, a phenotype that
correlated with a nearly complete loss of demethylated PP2A in
most mammalian tissues. PP2A activity and brain phosphopro-
teome were also altered in PME-1(–/–) mice. These data indicate
that dynamic methylation is required for proper PP2A function in
vivo.
Materials and Methods
Generation of PME-1(2/2) Mice
The PME-1 gene was obtained as part of a commercial BAC
clone (Invitrogen). The gene disruption construct was generated
using PCR-amplified 59 and 39 homologous recombination
fragments surrounding exon 7, which codes for amino acids
134–185 (including the catalytic serine nucleophile Ser
156) of the
PME-1 gene. The 59 and 39 homologous recombination fragments
were subcloned into the NotI and BamHI sites (59) and XhoI and
internal HindIII sites (39) of the pKO scrambler NTKV-1901
vector. Primers for 59 homologous end: 59-GC GCGGCCGC
CAC TGG CAG ACA CTC TCT CGC-39 (forward, with NotI
site) and 59-GC GGATCC CTC ACA GCT ATC TCC TTT
ACC-39 (reverse, with BamHI site). Primers for the 39 homologous
end: 59-GC CTCGAG GAG ACT CAT ATT GGA AGC TGG-
39 (forward, with XhoI site) and 59-CAA CAG GGC TGC TAA
CAC AGG-39 (reverse). Homologous recombinant 129SvJ
embryonic stem cell clones were identified by Southern blot
analysis, and two such clones were used to generate chimeric mice
on a C57BL/6 background. Chimeras from one of the two clones
gave germline transmission of the mutated gene. All mice used in
this study were first or second generation offspring from
intercrosses of 129SvJ-C57BL/6 PME(+/2). All work performed
in mice was done in accordance with the guidelines of the
Institutional Animal Care and Use Committee of The Scripps
Research Institute.
Genotyping of PME-1(+/+), (+/2) and (2/2) mice
For Southern blotting, genomic DNA was digested with HindIII
and separated on a 1% agarose gel. Fragments were transferred to
nylon membrane and probed with 59 external probe. An external
,330 bp probe was generated by PCR using the PME-1 genomic
BAC clone as template and the following primers: 59-CAG TTA
GCT AGG ATG TGC-39 (forward primer 39), 59-CCA GAG
GAA GTA AAC AGG-39 (reverse primer 39), 59-TCT GGT
GGG CTT ATA CCG-39 (forward primer 59) and 59-TTC TTT
TCT GGT CTT GCT TCC-39 (reverse primer 59).
32P-labeled
probe was hybridised overnight at 65uC.
PCR genotyping was performed using the following primers:
PME-1(+/+) primer set: 59-G GTG TCT TCC TCC AGC ACT
C-39 and 59-CCA TAC CAG GGG ACC TCC TAC-39; PME-
1(2/2) primer set: 59-GTC ACA GGG GCA AAA CTG TC-39
and 59-GCT CCC GAT TCG CAG CGC ATC-39 that gave
PCR products of 259 and 360 bp, respectively. After initial
denaturation at 94uC for 4 min, PCR amplification was
performed at a denaturing temperature of 94uC for 30 sec and
followed by annealing at 60uC for 30 sec and extension at 72uC
for 30 sec (35 cycles).
Western Blotting
Tissue homogenates were centrifuged at 100,000g for 45 min at
4uC degrees to generate membrane and soluble fractions. Soluble
fraction from each tissue was analysed by standard SDS-PAGE
(10% NuPAGE Bis-Tris gel, Invitrogen) and western blotting
procedures (incubation with the primary antibodies was carried
out overnight at 4uC and with the secondary antibodies for 1 hour
at room temperature). Polyclonal anti-PME-1 was generated in
rabbit against a PME-1-GST fusion protein. Anti-PP2A structural
(A), regulatory (B and B9) and catalytic (total, methylated and
demethylated) subunit antibodies were from Upstate. An anti-
phosphotyrosyl phosphatase activator protein (PTPA) antibody
was obtained from Upstate and an anti phospho-PP2A (Tyr
307)
antibody was obtained from Santa Cruz. Immunoblots incubated
with anti-tubulin (Sigma) were carried out as appropriate for
loading control (not shown in the figures for the sake of clarity) and
taking into account for band quantification as detailed in the
corresponding legends.
PP2A Activity Assays
Phosphopeptide substrate assay. Phosphatase activity of E18
tissue homogenates was determined using the phosphopeptide
KRpTIRR as a substrate with a PP2A immunoprecipitation
phosphatase assay kit (Upstate) following the manufacturers
recommendations. Free PO4
22 generated was quantified by
measurement of the absorbance at 595 nm after addition of
malachite green-molibdate reagent. A standard curve with free
phosphate was used to determine the amount of phosphate
generated. p-Nitrophenylphosphate (pNPP) assay. Phosphatase
Role of PME-1 in PP2A Function
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previously described [25,33]. PP2A was immunoprecipitated with
a PP2A antibody (Upstate) and protein A-agarose beads (Upstate)
from 2 mg of E18 tissue homogenates. Washed beads were
resuspended in assay buffer (50 mM Tris?HCl pH=8.5, 1.0 mM
DTT, 10 mM MgCl2 and 0.10 mg/mL BSA) and incubated in
presence of 10 mM pNPP at 37uC for 20 min. The reaction was
terminated by addition of an equal volume of Na2CO3 1.0 M and
absorbance was measured at 405 nm.
Phosphoproteomic analysis of mouse brain tissue
E18 brains from either PME-1(+/+)o r( 2/2) mice were
homogenized in Trizol (Invitrogen) and proteins isolated following
the manufacturers directions. The protein pellet was reconstituted
in 75 mL of 6M guanidine?HCl (Gu?HCl) with phosphatase
inhibitors (Sigma) and solubilized at 60uC for 30 min. Debris was
pelleted by centrifugation and protein concentration was mea-
sured in the supernatant using a Bradford-based protein assay
(Biorad). One milligram of total protein was brought to pH 8 by
addition of 100 mM NH4HCO3, reduced with 10 mM dithio-
threitol by incubation for 45 min at 60uC and alkylated with
20 mM iodoacetamide for 45 min in the dark. Proteomes were
diluted with 100 mM NH4HCO3 to a final Gu?HCl concentration
of 1 M and digested with trypsin (Promega, Madison, WI)
overnight at 37uC. As an internal standard, the peptide
FLApTGDGAR was added to each extract. Peptides were
desalted using SPE columns (Waters, Milford, MA), spiked with
a second standard peptide (LIEDAEpYTAK), and concentrated
by vacuum centrifugation to a volume of 50 mL. Reductive
amination was performed as described [34], with modifications.
Briefly, desalted peptides (50 mL) from PME-1(+/+) were added to
450 mL 1 M HEPES buffer (pH 7.5), mixed with 40 mL
formaldehyde (4% in water), vortexed, and then mixed immedi-
ately with 40 mL of freshly prepared cyanoborohydride (260 mM).
The mixture was vortexed again and then allowed to react for
10 min. Tryptic peptides from PME-1(2/2) were labelled in a
similar manner using d2-formaldehyde and sodium cyanobor-
odeuteride (Sigma-Aldrich). Afterwards, peptides were desalted,
combined and then subjected to strong cation exchange (SCX)
chromatography [35]. SCX fractions containing phosphopeptides
were then analyzed using an automated immobilized metal affinity
chromatography (IMAC)-HPLC/MS platform [36] coupled to an
LTQ Orbitrap mass spectrometer (San Jose, CA). The mass
spectrometer was operated in data dependent mode such that the
top 5 most abundant ions in each MS scan (resolution=100,000)
were subjected to MS/MS (collision energy=35%). MS/MS were
searched using the SEQUEST algorithm [37] against a sub-
database of human, mouse and rat proteins derived from the
NCBI non-redundant protein database.
Results
Targeted disruption of the PME-1 gene
To generate mice lacking PME-1 [PME-1(2/2) mice], the
exon that encodes amino acids 134–185, including the conserved
G154HSMG158 motif that contains the catalytic serine nucleophile,
was deleted by homologous recombination (Fig. 1A). Two
homologously recombined 129S6/SvEv embryonic stem cell
clones were identified by Southern blotting (Fig. 1B) and used to
generate chimeric mice on a C57BL/6 background. One of these
clones gave germline transfer of the mutated gene (Fig. 1C) and
was used to create PME-1(2/2) mice on an outbred background.
Western blotting with an anti-PME-1 antibody confirmed the
absence of PME-1 protein in PME-1(2/2) mice (Fig. 2A).
Postnatal Lethality in PME-1(2/2) Mice
At the moment of birth, PME(2/2) mice showed no obvious
abnormalities. However, these animals did not commence normal
breathing or suckling behaviour and invariably died during first
day of birth (Fig. 2B, upper panel). Further examination of animals
on the day prior to birth (embryonic day 18.5) revealed the
expected Mendelian frequency of genotypes [total pups: 128;
PME(+/+)=34 (26.6%), PME(+/2)=64 (50%), PME(2/2)=41
(24.2%)], with all genotypes appearing phenotypically normal.
(Fig. 2B, lower panel). These data indicate that PME-1(2/2) mice
develop normally in utero, but are incapable of surviving post-
natal.
PME-1 is the primary enzyme responsible for the in vivo
demethylation of the catalytic subunit of PP2A
PME-1 has been described as the enzyme that specifically
demethylates the catalytic subunit of mammalian PP2A based on in
vitro data using either reconstituted systems [22] or in lysates from
PME-1-expressing bacteria [23]. However, in vivo verification of this
hypothesis has remained lacking. We compared the levels of
methylated and demethylated PP2A in tissues from PME-1(+/+)
and (2/2) mice using methylation-specific antibodies. Brain
extracts from PME-1(2/2) mice contained essentially no demeth-
Figure 1. Generation of PME-1(2/2) mice. (A) Genomic structure
surrounding the deleted exon-7 that encodes amino acids 134–185 of
the PME-1 protein. Only relevant restriction sites are designated. (B)
Southern blot analysis of HindIII-digested genomic DNA using the
indicated external probe, where the 4.6 and 8.8 kb bands correspond to
PME-1(+/+) and (2/2) genotypes, respectively. (C) PCR analysis of
mouse genomic DNA, where the 250 and 360 bp bands correspond to
PME-1(+/+) and (2/2) genotypes, respectively.
doi:10.1371/journal.pone.0002486.g001
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brain tissue of PME-1(2/2) mice occurred without significant
changesintotalPP2Alevels(Fig.3A).Thepercentage ofmethylated
and demethylated PP2A was estimated in brain tissue from PME-
1(+/+)a n d( 2/2) mice by comparing the signals of these proteins
before and after treatment with strong base (0.1 M NaOH) to
chemically cleave the methylester bond. These studies estimated
that ,40% and .95% of PP2A exists in the methylated state in
PME-1(+/+) and (2/2) brains, respectively (Fig 3B). One
surprising finding is the apparent lack of net increase of the
methylated signal in PME-1(2/2) brains. One possible reason for
this result could be the presence of another C terminal modification
that hampers recognition by the antibody such as the phosphor-
ylation at Tyr
307 (although none of our attempts succeeded in
providing direct evidence of its presence) or at Thr
304,t h e
importance of which has been recently suggested [38]. Alternative-
ly, dissimilar systems may differ in their suitability for visualization
of changes in methylation. In this regard, for example, no change in
the methylation levels of C subunit was observed in the RNAi-
mediated knocked down of PME-1 in HeLa cells [32].
Peripheral tissues from PME-1(–/–) mice, such as heart and
liver, also showed a dramatic decrease in the levels of
demethylated PP2A; however, some residual signals for this form
of the enzyme could be detected in the absence of PME-1 (Fig. 3C).
In peripheral tissues, a significant reduction in total PP2A levels
was also observed (Fig. 3C).
Expression levels of structural and regulatory subunits of
PP2A in PME-1(+/+) and (2/2) mice
Ablation of the catalytic (C) subunit of PP2A causes disappear-
ance of all structural and regulatory PP2A subunits in Drosophila
[8]. Therefore, we studied whether the elimination of the
demethylated pool of PP2A exerted any effect on the expression
of either the scaffold (A) or regulatory (B and B9) subunits. In
brain, no alterations in PP2A structural or regulatory subunits
were observed in PME-1(2/2) mice (Fig. S1). The structural
subunit PP2A A was modestly decreased in heart and liver of
PME-1(2/2) mice, possibly reflecting the diminished levels of
total PP2A C expression in these two tissues (Fig. 3C).
Decreased PP2A activity in PME-1(2/2) tissues
We next investigated the influence of the methylation state of
PP2A on catalytic activity using a phosphopeptide substrate
(KRpTIRR).Immunoprecipitated PP2A from PME-1(2/2) tissues
showed significant reductions in phosphatase activity, which were
most dramatic in brain tissue (,4-fold reduction) (Fig. 4A). More
than 80% ofthe phosphataseactivitymeasured inthis assayforboth
PME-1(+/+) and (2/2) tissues was inhibited by the PP2A inhibitor
okadaic acid, confirming that it derived from the PP2A enzyme
(Fig. 4B). Previous research has not revealed a direct link between
the methylation state of PP2A and catalytic activity, although none
of these studies were conducted with a fully methylated enzyme
expressed in native mammalian tissues. Instead, it has been
proposed that PP2A methylation might affect phosphorylation at
Tyr
307, which has beenfound to inactivate PP2A [17].We therefore
attempted to measure the contribution of phosphorylated PP2A to
the total phosphatase activity in PME-1(+/+)a n d( 2/2) brains by
immunoprecipitation with an anti-phosphotyrosine antibody.
Western blotting of the beads and the supernatant with an antibody
that specifically recognizes phospho-tyrosine 307 of PP2A, as well as
with antibodies for the different forms of the catalytic PP2A subunit
(total, methylated and demethylated) did not yield any appreciable
signal in immunoprecipitated samples from either PME-1(+/+)o r
(2/2) tissue. Instead, signals for total, methylated and demethyl-
ated PP2A were exclusively observed in the supernatant fraction (no
signal was observed for phospho-tyrosine 307 PP2A in any sample).
These data indicate that phosphorylation of Tyr
307 is not a major
steady-state modification on PP2A in brain tissue of PME-1(+/+)
and (2/2) mice.
Another mode of regulation of PP2A occurs through binding to
the PP2A phosphatase activator (PTPA) protein. PTPA is highly
conserved from yeast to human and was initially named based on
its ability to stimulate the basal level of phosphotyrosyl
phosphatase activity of PP2A [39–41]. However, recent findings
suggest that the more likely physiological function of PTPA is to
reactivate the Ser/Thr phosphatase activity of an inactive form of
PP2A [33,42,43]. Therefore, we analyzed whether the observed
differences in PP2A activity between PME(+/+) and (2/2) tissues
could be attributed to variations in the levels of PTPA. However,
Figure 2. Deletion of PME-1 leads to postnatal lethality in mice. (A) Western blot analysis showing the absence of PME-1 protein in tissues
from PME-1(2/2) mice. (B) upper panel, P0 littermates with genotypes shown [note dead pup for PME-1(2/2)]; lower panel, E18 embryos with
genotypes shown. Scale bar, 1 cm.
doi:10.1371/journal.pone.0002486.g002
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brain tissue from PME(+/+) and (2/2) mice (Fig. 4C).
Taken together, these data suggest that the decreased
phosphopeptide phosphatase activity observed in PME-1(2/2)
mice may be directly related to the absence of demethylated forms
of the PP2A catalytic subunit. In order to establish whether the
defective activity of PP2A was observed with other classes of
substrates, we tested the activity of immunoprecipitated PP2A
Figure 3. Impact of PME-1 deletion on the methylation state and expression level of the PP2A catalytic (C) subunit. (A) Expression of
the different forms of the PP2A catalytic (C) subunit in brain tissue from PME-1(+/+) and (2/2) mice (harvested from E18 embryos). Western band
quantification results are reported as their ratio over tubulin as loading control (not shown) as mean6standard error (SE) for at least four
independent experiments. ***p,0.001, for PME(+/+) versus (2/2) samples. (B) Estimation of the percentage of steady-state methylation in brain
tissue from PME-1(+/+) and -(2/2) E18 embryos. The fraction (x) of methylated C subunit in the original samples is defined as the ratio of the
demethylated C subunit signal in untreated versus NaOH-treated samples. This fraction was used to calculate the steady-state methylation level
(%=1006[12x]). The results are presented as mean values6SE of three independent experiments from which one representative gel is shown. (C)
Expression of the different forms of the PP2A C subunit in liver and heart tissue from PME-1(+/+) and -(2/2) E18 embryos. Western band
quantification results are means6SE for at least two independent experiments. *p,0.01, **p,0.005, ***p,0.001 for PME-1(+/+) versus (2/2)
samples.
doi:10.1371/journal.pone.0002486.g003
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(pNPP). Interestingly, no significant differences were observed in
pNPPase activity in brain tissue from PME-1(+/+) and (2/2)
mice (Fig. 4D). Similar results were obtained when the okadaic
acid-sensitive portion of pNPPase activity was taken into account
(Fig. 4D, inset), which accounted for approximately 60% of the
total pNPPase activity in brain tissue from PME-1(+/+) and (2/2)
mice These data suggest that the methylation state of PP2A
selectively impacts the productive binding/recognition of phos-
pho-peptide substrates rather than causing inherent defects in
catalytic activity. A possibility that cannot be excluded from the
present results is that the decrease in activity can be due to
differential composition of the immunoprecipitates between the
PME-1-(+/+) and (2/2) samples. Although statistically significant
variations in the levels of the immunoprecipitated C subunit (total
and methylated) were not detected by western blot (data not
shown), their different composition cannot be ruled out, especially
since this phenomenon has been widely described to influence
PP2A activity [4,8–13]. Therefore, instead of pursuing further
characterization of in vitro activity towards a wide range of
substrates (which may or may not reflect the physiological
situation), we focused our efforts on profiling differentially
phosphorylated proteins in the PME-1(+/+) and (2/2) mice.
Analysis of candidate PP2A substrates by
phosphoproteomic mapping in brain tissue from PME-
1(+/+) and (2/2) mice
Methylation state of PP2A has been previously involved in the
specific recognition of substrates [4,26]. This fact, together with
our data indicating impaired hydrolysis of a phosphopeptide
substrate in tissues from PME-1(2/2) mice, suggested that this
animal model might represent a suitable model to identify PP2A
substrates for which PP2A demethylation (or methylation/
demethylation cycling) is required. To begin to test this idea, we
conducted a comparative phosphoproteomic mapping of brain
tissue from PME-1(+/+) and (2/2) mice. Proteins were extracted
from whole brain with Trizol, reduced, alkylated and digested with
trypsin. To allow quantification, the mixture of peptides was
isotopically labeled as detailed in the materials and methods
section. After labeling, the PME-1(+/+) and (2/2) proteomes
were combined, subjected to SCX chromatography [35] and
analyzed using an automated IMAC-HPLC/MS platform [36]
coupled to an LTQ Orbitrap mass spectrometer. Following this
methodology, phosphopeptides present in both proteomes appear
in the mass spectrum as doublets separated by 6 m/z units per
modified primary amine group in the peptide. Phosphopeptides
that are unique to one or the other proteome appear as singlets.
After phosphopeptide identification using SEQUEST [37], the
ratio between the area of the peaks of the heavy and light version
of the same phosphopeptide was used for quantification.
Reproducibility of the peptide extraction, derivatization and
analytical methodology was ensured by analyzing three d0- and
d3- labelled independent proteomes. The proteins identified as up-
or down-regulated in at least two of three independent
experiments with a difference between PME-1(+/+) and (2/2)
samples of at least two fold were considered significant hits and
were manually validated (Tables 1 and 2).
Using the aforementioned criteria, we successfully sequenced 40
phosphopeptides corresponding to 38 proteins that differed
between PME-1(+/+) and (2/2) samples. The majority of the
identified proteins are known phosphoproteins (with the exception
of phosphacan). Interestingly, in addition to detecting some known
PP2A interacting proteins and/or substrates [e.g., MAP1B
[44,45], neurofilament protein [46] and Cdc2 [4,47], we have
also characterized previously unidentified phosphorylation sites as
candidates for PP2A action. Identified phosphoproteins mainly fell
into three categories based on predicted function: proteins
involved in cellular communication, transcriptional regulation
and cellular structure. A limited number of proteins with roles in
the DNA replication and protein synthesis (BM28 homologue and
the eukaryotic initiation factor 5, respectively) as well as metabolic
functions (phosphorylcholine transferase B) were also identified.
The phosphoserine/threonine proteins down-regulated in PME-
1(2/2) (or phosphorylated on tyrosine residues, of which there
were three examples) likely represent indirect consequences of
alterations in PP2A activity in PME(2/2) mice. Conversely, those
elevated in PME-1(2/2) brain tissue could be either substrates of
a hyperactive kinase which activity is negatively regulated by PP2A
or, alternatively, candidate direct substrates of PP2A.
A closer examination of the list of putative direct substrates of
PP2A (i.e., phosphoproteins elevated PME(2/2) brain tissue)
Figure 4. PP2A phosphatase activity in tissues from PME-1(+/+) and (2/2) mice. (A) PP2A was immunoprecipitated from different tissues of
PME-1(+/+) and (2/2) E18 embryos and phosphatase activity towards the phosphopeptide substrate KRpTIRR was determined. Results are expressed
in pmol of phosphate released per 10 min and 250 mg of protein and represent mean values6SE for at least three independent experiments
(***p,0.001, *p,0.01 for PME-1(+/+) versus (2/2) samples). (B) Inhibition of phosphatase activity of brain immunoprecipitated PP2A by okadaic acid.
Results represent mean values6SE of two independent experiments performed in duplicate (***p,0.001 for phosphatase activity in absence versus
presence of okadaic acid). (C) PTPA expression in brains from PME-1(+/+) and (2/2) E18 embryos. Blot is representative of two independent samples.
D, PP2A was immunoprecipitated from brain of PME-1(+/+) and (2/2) E18 embryos and phosphatase activity towards p-nitrophenylphosphate
(pNPP) in presence or absence of okadaic acid was determined. Results are expressed in nmol of p-nitrophenol (pNP) released per 20 min and 2 mg
of protein and represent mean values6SE for three independent experiments. Inset shows that the okadaic acid-sensitive fraction (obtained by
subtraction of okadaic acid non-sensitive pNPPase activity from total pNPPase activity) of pNPPase activity (like the total pNPPase activity) was
equivalent between PME(+/+) and (2/2) samples (*p,0.01 for phosphatase activity in absence versus presence of okadaic acid).
doi:10.1371/journal.pone.0002486.g004
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General class
Name, accession number (gi) and






Adaptor Molecules Gab1 (10433473) (Ser 98) 2.5 Yes
a
GEF Dock7 (Rac GEF) (12698087) (Ser 600) 2.5 No
Protein kinases Cdc2 (4502709) (Tyr 15) 2.7 Yes
b
SNIL (12643489) (Ser 437) 3.33 No
DNA replication BM28 homolog (2183319) (Ser 27) 2.6 No
Transcription factors and
transcriptional regulators
TF1B (3183181) (Ser 501) 3.3 No
Tubby-superfamily protein (9502080) (Ser 1377) 2.8 No
Protein synthesis Translation initiation complex EIF5 (9910214) (Ser 10 and 227) 2.5 No
Structural/Cytoskeletal Lamin B1 (6754556) (Ser 23) 3.0 No
Unkown AK010820 (12846529) (Ser 235) 2.5
KIAA1757 (12698059) (Ser 39) 2.3
KIAA0386 (2224713) (Ser 21) 3.1
doi:10.1371/journal.pone.0002486.t001
Table 2. Phosphoproteins decreased in PME-1(2/2) brains
Cellular communication and
signal transduction
Adaptor/Scaffold Molecules X11 (423056) (Tyr 135) 0.3 No
Neuronal protein 4.1 (2224617) (Ser 784) 0.4 No
Palmitoylated membrane protein 2 (4885493) (Ser 42) 0.4 No
Receptors Mglu7 (547904) (Ser 900) 0.4 No
Phosphacan (6755250) (Ser 276) 0.1 No
GAPs GAP120 (6753930) (Ser 225) 0.3 No
Vesicle Trafficking Syntaxin (9297065) (Ser 287 and 288) 0.3 Yes
c
Reticulon (12643485) (Ser 352) 0.4 No
Transcription factors and
transcriptional regulators
RYBP (9790205) (Ser 201) 0.4 No
PC4 AND SFRS1 (11024645) (Ser 106) 0.5 No
Lbh (12052926) (Ser 163) 0.2 No
MeCP2 (12083609) (Ser 80) 0.3
ZBP89 (12585539) (Ser 306) 03 No
Structural/Cytoskeletal MAP1B (5174525) (Ser 1260) 0.4 Yes
d
Neurofilament protein (8393823) (Ser 766) 0.1 Yes
e
Actin binding proteins Drebrin (2498314) (Ser 659) 0.3 No
Drebrin-like (7304993) (Thr 296 and Ser 274) 0.3 No
Synaptopodin (2654323) (Ser 19) 0.1 No
Metabolism CTPU (12643330) (Ser 315 and 319) 0.5 No
Unkown KIAA1582 (10047239) (Ser 515) 0.3
AK003611 (12834382) (Ser 57) 0.4
AK009886 (12844957) (Ser 43) 0.4
AK011522 (12847703) (Ser56) 0.3
ArfGAP protein (11691875) (Ser 360) 0.4
Unclassified GAP43 (8393415) (Ser 96) 0.3 Yes
f
HASPP28 (12018258) (Tyr 17) 0.3
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to the pre-mature death observed in PME-1(2/2) mice. Gab1
plays an essential role in several steps of mammalian development.
Forexample,inGab1(2/2)mice,migrationofmyogenicprecursor
cells is impaired and muscles in the diaphragm are missing [48].
Dock 7 plays a critical role in axon development [49]. B-type lamins
are found in all cell types and are expressed throughout
development. In the nucleus, lamin B1 binds directly to chromatin
and histones and has a direct role in DNA synthesis. An essential
role for lamin B was confirmed by the analysis of mice deficient in
this protein, which die in the perinatal period with defects in lung
and bone [50,51]. Two additional proteins with altered phosphor-
ylation in PME-1(2/2) mice, Cdc2 and the translation initiation
factor 5 (eIF5), exert a broader influence over cellular processes by
governing entrance into mitosis [47] and initiation of protein
synthesis [52,53], respectively.
Discussion
The post-translational carboxylmethylation of the catalytic
subunit of PP2A appears to exist in all eukaryotic organisms from
yeast to human and, therefore, likely represents a key mechanism
for regulating PP2A activity. Methylation has been hypothesized
to influence the association of the PP2A heterodimer with different
B regulatory subunits, which in turn control PP2A intracellular
location and recognition of substrates. This model has been
supported by various in vitro biochemical studies [14,27,28,30] and
genetic experiments in yeast [25,26,29]. The latter results
illuminated an important role for the primary PP2A methyltrans-
ferase in survival, but yeast lacking the major PP2A methylesterase
(Ppe1) were without apparent phenotypic defect [26]. The
endogenous functions of methylated/demethylated forms of
PP2A in mammalian systems have not yet been explicitly tested.
Here we have investigated the function of mammalian PME-1
gene by deleting it from mice. PME-1 gene deletion resulted in
perinatal lethality, a phenotype that correlated with essentially
complete loss of the demethylated form of PP2A in brain tissue.
Further studies revealed that PME-1(2/2) brain tissue also
possessed significantly reduced PP2A activity with phosphopeptide
substrates and diminished quantities of PP2A holoenzyme
complexes. To begin to assess the net biochemical and cellular
effects of these changes in PP2A activity and complex assembly, we
performed a comparative phosphoproteomic analysis of brain
tissue from PME-1(+/+) and (2/2) mice. Several phosphopro-
teins were identified that exhibited either elevated or reduced
signals in PME-1(2/2) brains, suggesting that the absence of
demethylated PP2A invokes widespread alterations in phosphor-
ylation networks. Collectively, we interpret these results to indicate
that demethylated PP2A plays essential non-redundant functions
that cannot be undertaken by the methylated pool of this protein.
This statement implicitly assumes that methylated PP2A is the
main, if not the unique, PME-1 substrate. However, the data
available about the absolute substrate specificity of PME-1 are far
for being conclusive. Therefore, the possibility of the existence of
alternative substrates that could potentially play a role in the
lethality and/or differential PP2A activity can not be unequivo-
cally ruled out. Having said this, and even in the presence of other
potential PME-1 substrates, it is clear that no other enzyme can
undertake the role of PME-1 in PP2A demethylation, since non-
methylated PP2A is virtually absent from PME-1(2/2) tissues.
Considering the importance that has been attributed to the
methylation state of PP2A, it seems logic to hypothesize that at
least part of the effects are due to the disruption of the PP2A
methylation state. Precisely how the absence of demethylated
PP2A leads to reductions in enzyme activity or differential
recognition of substrates remains unclear. Possible explanations
could be that proper functioning and stability of PP2A complexes
requires the dynamic ability to switch between methylated and
demethylated forms during the substrate binding/catalytic cycle.
In the absence of PME-1, this cycling would be blocked, resulting
in an imbalanced accumulation of methylated forms of PP2A.
Another (and not necessarily mutually exclusive) explanation is
that PME-1 is, itself, a key component of PP2A complexes in vivo.
Potentially consistent with this latter idea, PME-1 has been shown
to regulate active PP2A C subunit generation and holoenzyme
assembly [31] and to stably associate with ‘‘inactive’’ forms of
PP2A complexes in tissues [32,42], suggesting that this protein
may confer a regulatory effect on PP2A activity through both
binding interactions as well as catalysis. This final hypothesis could
be directly tested by attempting to rescue the biochemical and
cellular phenotypes observed in PME-1(2/2) mice with catalyt-
ically active and inactive (e.g., Ser
156-to-Ala) forms of the PME-1
enzyme. Such next-generation studies should further refine our
understanding of the evidently critical role that post-translational
methylation plays in regulating PP2A activity in vivo.
Supporting Information
Figure S1 Expression of PP2A structural and regulatory
subunits (A, B, and B9) in PME-1(+/+) and (2/2) tissues. Tissues
were harvested from E18 embryos.
Found at: doi:10.1371/journal.pone.0002486.s001 (0.29 MB
PDF)
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